Growth inhibition and transcriptional effects of ribavirin in lymphoma
Por:
Dominguez-Gomez, Guadalupe, Cortez-Pedroza, Dominique, Chavez-Blanco, Alma, Taja-Chayeb, Lucia, Hidalgo-Miranda, Alfredo, Cedro-Tanda, Alberto, Beltran-Anaya, Fredy, Diaz-Chavez, Jose, Schcolnik-Cabrera, Alejandro, Gonzalez-Fierro, Aurora, Duenas-Gonzalez, Alfonso
Publicada:
1 ene 2019
Resumen:
Ribavirin exhibits inhibitory effects on the epigenetic enzyme enhancer of zeste homolog 2 (EZH2), which participates in lymphomagenesis. Additionally, preclinical and clinical studies have demonstrated the anti-lymphoma activity of this drug. To further investigate the potential of ribavirin as an anticancer treatment for lymphoma, the tumor-suppressive effects of ribavirin were analyzed in lymphoma cell lines. The effects of ribavirin on the viability and clonogenicity of the B-cell lymphoma cell line Pfeiffer (EZH2-mutant), Toledo (EZH2 wild-type) and cutaneous T-cell lymphoma Hut78 cell line were assessed. Expression of EZH2 and trimethylation status of histone 3, lysine 27 trimethylated (H3K27m3) was also determined in response to ribavirin. The transcriptional effects of ribavirin on Hut78 cells were analyzed by microarray expression and the results were validated by reverse transcription-quantitative polymerase chain reaction, western blotting and knockout of signal transducer and activator of transcription 1 (STAT1). The results of the present study demonstrated that ribavirin suppressed the growth and clonogenicity of cells in a dose-dependent manner. Ribavirin did not affect the expression of EZH2 nor altered its activity as evaluated by H3K27 trimethylation status. Furthermore, the results of transcriptome analysis indicated that the majority of the canonical pathways affected by ribavirin were associated with the immune system, including eantigen presentation, communication between innate and adaptive immune cells' and 'cross-talk between dendritic and natural killer cells'. The results of gene expression analysis were confirmed, by demonstrating at the RNA and protein levels, downregulation of stearoyl-CoA desaturase and upregulation of STAT1. Depletion of STAT1, which was proposed as a key regulator of the aforementioned pathways, exerted growth inhibitory effects almost to the same extent as ribavirin. In conclusion, ribavirin was proposed to exert growth inhibitory effects on lymphoma cell lines, particularly Hut78 cells, a cutaneous T-cell lymphoma cell line. Of note, these effects may depend on, at least in part, the activation of canonical immune pathways regulated by the key factors STAT1 and interferon-?. Our results provide insight into the anti-lymphoma potential of ribavirin; however, further investigations in preclinical and clinical studies are required to determine the effectiveness of ribavirin as a therapeutic agent for treating lymphoma. © 2019 Spandidos Publications. All rights reserved.
Filiaciones:
Dominguez-Gomez, Guadalupe:
Division of Basic Research, National Cancer Institute (INCAN), Mexico City, 14080, Mexico
Natl Canc Inst INCan, Basic Res Div, Mexico City 14080, DF, Mexico
Cortez-Pedroza, Dominique:
Division of Basic Research, National Cancer Institute (INCAN), Mexico City, 14080, Mexico
Natl Canc Inst INCan, Basic Res Div, Mexico City 14080, DF, Mexico
Chavez-Blanco, Alma:
Division of Basic Research, National Cancer Institute (INCAN), Mexico City, 14080, Mexico
Natl Canc Inst INCan, Basic Res Div, Mexico City 14080, DF, Mexico
Taja-Chayeb, Lucia:
Division of Basic Research, National Cancer Institute (INCAN), Mexico City, 14080, Mexico
Natl Canc Inst INCan, Basic Res Div, Mexico City 14080, DF, Mexico
Hidalgo-Miranda, Alfredo:
Cancer Genomics Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, 14610, Mexico
Natl Inst Genom Med INMEGEN, Canc Genom Lab, Mexico City 14610, DF, Mexico
Cedro-Tanda, Alberto:
Cancer Genomics Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, 14610, Mexico
Natl Inst Genom Med INMEGEN, Canc Genom Lab, Mexico City 14610, DF, Mexico
Beltran-Anaya, Fredy:
Cancer Genomics Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, 14610, Mexico
Natl Inst Genom Med INMEGEN, Canc Genom Lab, Mexico City 14610, DF, Mexico
Diaz-Chavez, Jose:
Division of Basic Research, National Cancer Institute (INCAN), Mexico City, 14080, Mexico
Natl Canc Inst INCan, Basic Res Div, Mexico City 14080, DF, Mexico
Schcolnik-Cabrera, Alejandro:
Division of Basic Research, National Cancer Institute (INCAN), Mexico City, 14080, Mexico
Natl Canc Inst INCan, Basic Res Div, Mexico City 14080, DF, Mexico
Gonzalez-Fierro, Aurora:
Division of Basic Research, National Cancer Institute (INCAN), Mexico City, 14080, Mexico
Natl Canc Inst INCan, Basic Res Div, Mexico City 14080, DF, Mexico
Duenas-Gonzalez, Alfonso:
Unit of Biomedical Research, Institute of Biomedical Research, National Autonomous University of Mexico (UNAM)/INCAN, 22 San Fernando Street, Mexico City, 14080, Mexico
Natl Autonomous Univ Mexico UNAM, Inst Biomed Res, Unit Biomed Res, INCAN, 22 San Fernando St, Mexico City 14080, DF, Mexico
|